Concepedia

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Alexander Drilon, Jeffrey W. Clark, Jared Weiss, Sai‐Hong Ignatius Ou, D. Ross Camidge, Benjamin Solomon, Gregory A. Otterson, Liza C. Villaruz, Gregory J. Riely, Rebecca S. Heist,

Nature Medicine · 2020 · 393 citations · 43 references

Open access

Concepts

MedicineOncologyPharmacologyCancer GeneticsChemotherapyMolecular OncologyCancer Cell SignalingLung CancerLung Cancer PharmacotherapyOncology PharmacologyPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsAnticancer ActivityMet Exon 14 Skipping MutationsMet-targeted Therapy

References

43

The National Comprehensive Cancer Network

William T. McGivney · Cancer · 1998 · 16.9K citations

Medicine, Oncology, Clinical Informatics +15

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al. · American Journal of Clinical Oncology · 1982 · 11.6K citations

Pharmacy, Oncology, Medical Oncology +8

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text

Medicine, Oncology, Pharmacology +13

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · New England Journal of Medicine · 2017 · 5.3K citations · Full text

Medicine, Oncology, Pharmacology +16